Equillium Results Presentation Deck
Next Steps
Key learnings from EQUALISE Type B lupus nephritis interim data:
Itolizumab continues to demonstrate a favorable safety and tolerability profile at 1.6 mg/kg dose through six months
of treatment
0
Based on compelling data and KOL feedback, Equillium plans to:
Continue enrollment in the EQUALISE study-topline data anticipated mid-2023
Continue analysis of serologies and biomarkers such as soluble ALCAM to response rates
Prepare for later stage development that can support product registration
•
Emerging product profile suggests differentiation in early, rapid, and deep responses in highly proteinuric patients
Adds to our conviction in the clinical activity of itolizumab and the potential to be an impactful therapy for patients
with severe immuno-inflammatory diseases
10
equillium
Based on interim data from 2 Sep 2022-subject to change:
Abbreviations: ALCAM activated leukocyte cell adhesion molecule: KOL key opinion leader
32View entire presentation